



**Undertaking regarding No Objection Certificate from Lending Scheduled Commercial Banks/
Financial Institutions for Scheme of Arrangement**

September 27, 2023

To,
The General Manager,
Department of Corporate Services,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400 001

Dear Madam/ Sir,

Re.: Scheme of Arrangement amongst Strides Pharma Science Limited (“Strides” or “Transferor Company 1” or “Demerged Company 1”) and Steriscience Specialties Private Limited (“Steriscience” or “Transferor Company 2” or “Demerged Company 2”) and Stelis Biopharma Limited (“Stelis” or “Transferee Company” or “Resulting Company”) and their respective shareholders (“Draft Scheme”), presented under Section 230-232 read with other applicable provisions of the Companies Act, 2013.

With reference to the proposed Draft Scheme, we hereby confirm that the Company has initiated the process for obtaining the No Objection Certificate from the lending Scheduled Commercial Banks/ Financial Institutions/ Debenture Trustees (as applicable) as required under Para A (2) (k) of Part I of SEBI Master Circular dated June 20, 2023, as amended, and the same shall be submitted to the Exchange before receipt of the No-objection Letter from the Stock Exchanges in terms of Regulation 37(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time.

Thanks & Regards,
For **Strides Pharma Science Limited**,

Manjula R.

Manjula Ramamurthy
Company Secretary
ICSI Membership No. A30515

